MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.410
0.000
0.00%
Opening 09:30 06/29 EDT
OPEN
1.410
PREV CLOSE
1.410
HIGH
1.410
LOW
1.410
VOLUME
103
TURNOVER
144
52 WEEK HIGH
12.90
52 WEEK LOW
1.110
MARKET CAP
60.61M
P/E (TTM)
-2.5278
1D
5D
1M
3M
1Y
5Y
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
Benzinga · 2d ago
BRIEF-Sab Biotherapeutics Announces Appointment Of Alexandra Kropotova As Chief Medical Officer
reuters.com · 06/06 12:39
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 06/06 12:34
SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit
In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City, Utah Dr. Christoph Bausch to share early R&D updates on SAB novel platform advancement toward developin...
GlobeNewswire · 05/31 12:30
--Chardan Capital Adjusts SAB Biotherapeutics' Price Target to $7 from $10, Keeps Buy Rating
MT Newswires · 05/13 11:07
SAB Biotherapeutics GAAP EPS of $0.02
SAB Biotherapeutics press release (NASDAQ:SABS): Q1 GAAP EPS of $0.02. Cash and cash equivalents were $22.4 million as of March 31, 2022, compared to $33.2 million on December 31, 2021.
Seekingalpha · 05/12 21:11
BRIEF-SAB Biotherapeutics Reports Q1 EPS Of $0.02
reuters.com · 05/12 20:23
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results
Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase 2 data for SAB-185 expected to be available later this year Sufficient cash anticipated...
GlobeNewswire · 05/12 20:15
More
No Data
Learn about the latest financial forecast of SABS. Analyze the recent business situations of SAB BIOTHERAPEUTICS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SABS stock price target is 9.10 with a high estimate of 12.40 and a low estimate of 7.00.
High12.40
Average9.10
Low7.00
Current 1.365
EPS
Actual
Estimate
-0.52-0.39-0.25-0.11
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 31
Institutional Holdings: 2.00M
% Owned: 4.66%
Shares Outstanding: 42.99M
TypeInstitutionsShares
Increased
14
131.58K
New
3
65.48K
Decreased
6
17.92K
Sold Out
9
1.47M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About SABS
SAb Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.

Webull offers kinds of SAB Biotherapeutics Inc stock information, including NASDAQ:SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.